Skip to Main Content

Paper Details

Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry.
Arthritis Res Ther
2
2021
Author NameAffiliation
Jakub Z??vadaInstitute of Rheumatology
Jakub Z??vada
  • 1 - 2

Datasets

Release 1.2